PhenomeX
Founded Year
2011Stage
Acq - Pending | AcquiredTotal Raised
$223.68MValuation
$0000About PhenomeX
PhenomeX (NASDAQ: CELL) is a biotechnology research company. It conducts research and aids drug development in the fields of cell and gene therapy, oncology, neurology, and more. The company was formerly known as Berkeley Lights. It was founded in 2011 and is based in Emeryville, California.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Expert Collections containing PhenomeX
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PhenomeX is included in 3 Expert Collections, including Synthetic Biology.
Synthetic Biology
238 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Digital Health
10,563 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
PhenomeX Patents
PhenomeX has filed 124 patents.
The 3 most popular patent topics include:
- Biotechnology
- Microfluidics
- Fluid dynamics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/24/2021 | 8/22/2023 | Microfluidics, Microscopy, Optical devices, Biotechnology, Nanotechnology | Grant |
Application Date | 6/24/2021 |
|---|---|
Grant Date | 8/22/2023 |
Title | |
Related Topics | Microfluidics, Microscopy, Optical devices, Biotechnology, Nanotechnology |
Status | Grant |
Latest PhenomeX News
Sep 21, 2023
News provided by Share this article Share toX Preliminary SpotLight™ Human Lambda reagent data to be showcased by GSK at the 16th annual PEACe Conference EMERYVILLE, Calif., Sept. 21, 2023 /PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL ), a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression. Molly Robinson, a senior scientist with GSK, will present data demonstrating how the SpotLight Human Fc, SpotLight Human Kappa and SpotLight Human Lambda reagents can be used in cell line development productivity assays on the Beacon platform. In this study, as an early access PhenomeX customer, GSK screened clones secreting IgG Lambda light chain monoclonal antibodies and clones secreting bispecific lambda-kappa antibodies. Additionally, the GSK team was able to characterize a variety of molecular formats using the library of SpotLight reagents, and they are excited to continue using these reagents to investigate complex molecular candidates. PhenomeX's fluorescent SpotLight reagents, which are non-destructive and certified as animal- component free, allow early productivity and product quality screens to be run in parallel across thousands of clonal populations. SpotLight™ Human Fc reagent binds to the Fc region of human antibodies SpotLight™ Human Kappa reagent binds to the kappa light chain of human antibodies Soon-to-be released SpotLight™ Human Lambda reagent binds to the lambda light chain of human antibodies As demonstrated by GSK, these reagents can be used individually for screening of monospecific antibodies or in combination to screen bispecific lambda-kappa antibodies. Dr. Robyn Emmins, the Scientific Director for Cell Line Development at GSK, commented: "The SpotLight Human Lambda reagent further expands the range of molecular formats we can screen using the Beacon; thus enabling a flexible Cell Line Development process, to support our rapidly diversifying Biopharmaceutical portfolio." Please see the Opto® Cell Line Development Workflow datasheet for additional information. The SpotLight™ Human Lambda reagent will be available for purchase after October 23, 2023. About PhenomeX Inc. PhenomeX is empowering scientists to leverage the full potential of each cell and drive the next era of functional cell biology that will advance human health. We enable scientists to reveal the most complete insights on cell function and obtain a full view of the behavior of each cell. Our unique suite of proven high-throughput tools and services offer unparalleled resolution and speed, accelerating the insights that are key to advancing discoveries that can profoundly improve the prevention and treatment of disease. Our award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. PhenomeX has no affiliation with Phenomenex, Inc. PhenomeX will be changing its name. All inquiries regarding Phenomenex, Inc. and/or its products should be directed to [email protected] . Forward-Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding PhenomeX or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. PhenomeX undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission. SOURCE PhenomeX
PhenomeX Frequently Asked Questions (FAQ)
When was PhenomeX founded?
PhenomeX was founded in 2011.
Where is PhenomeX's headquarters?
PhenomeX's headquarters is located at 5858 Horton Street, Emeryville.
What is PhenomeX's latest funding round?
PhenomeX's latest funding round is Acq - Pending.
How much did PhenomeX raise?
PhenomeX raised a total of $223.68M.
Who are the investors of PhenomeX?
Investors of PhenomeX include Bruker, Novo Nordisk, Celesta Capital, Sequoia Capital, Atinum Investment and 11 more.
Who are PhenomeX's competitors?
Competitors of PhenomeX include Enrich Biosystems and 2 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare PhenomeX to Competitors
Spher Fluidics provides Cyto-Mine technology, an integrated device that uses picodroplet technology and microfluidics to process heterogeneous mammalian cells. Each cell is encapsulated in a picodroplet containing growth media, which acts as a bioreactor to compartmentalize the cell and let it grow, eventually trapping secreted molecules such as antibodies, and enabling the selective screening of single cells to find rare lead candidates.
CellChorus is a biotechnology company. The company applies time-lapse imaging microscopy in nanowell grids (TIMING) platform with neural network-based detection to identify how cells move, activate, kill, and survive at single-cell resolution to provide an understanding of cellular function, state, and phenotype. It was founded in 2021 and is based in Houston, Texas.
Enrich Biosystems provides novel single-cell isolation technology to increase biomedical research. It develops TROVO, the cell discovery platform for time-lapse imaging, analysis, and cell capture. It also enables streamlining workflows and designing experiments that fit cell research needs. It was founded in 2018 and is based in Branford, Connecticut.
Samplix provides life sciences and medical research. The company develops a microfluidics instrument called Xdrop, which enables rapid and accurate functional analysis of cells with single-cell resolution. Xdrop technology for single-molecule enables single-DNA molecule sample preparation. Samplix was founded in 2013 and is based in Birkerod, Denmark.
LJL Biosystems, Inc. developed and manufactured automated instrumentation systems for clinical, research and drug development applications. The company was acquired by Molecular Devices Corporation (Nasdaq: MDCC) in August of 2000.
Agilent Technologies (NYSE: A) provides instruments, software, services, and consumables for the entire laboratory workflow, serving the life sciences, diagnostics, and applied chemical markets. The company was founded in 1999 and is based in Santa Clara, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
